Valuation: Glaukos Corporation

Market Cap 13.02B 11.67B 10.67B 9.74B 18.35B 1,224B 18.93B 129B 51.28B 653B 48.86B 47.81B 2,061B P/E 2026 *
-743x
P/E 2027 * 167x
Enterprise Value 12.87B 11.54B 10.55B 9.63B 18.14B 1,210B 18.71B 127B 50.69B 645B 48.3B 47.26B 2,037B EV / Sales 2026 *
16.5x
EV / Sales 2027 * 12.7x
Free-Float
96.36%
Yield 2026 *
-
Yield 2027 * -
1 day+3.19%
1 week-4.55%
Current month-4.55%
1 month+40.35%
3 months+32.63%
6 months+67.66%
Current year+100.86%
1 week 218.76
Extreme 218.765
255.18
1 month 146.38
Extreme 146.385
255.18
Current year 93.96
Extreme 93.96
255.18
1 year 80.9
Extreme 80.905
255.18
3 years 59.22
Extreme 59.22
255.18
5 years 33.33
Extreme 33.33
255.18
10 years 23.08
Extreme 23.075
255.18
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
President 50 01/04/2022
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Sell

Executive/Senior Manager

-1,527 0.0027%
25/9/26 Sell

Executive/Senior Manager

-1,615 0.0028%
16/9/26 Sell

Executive/Senior Manager

-1,457 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+3.13%-4.55%+177.28%+254.30% 13.02B
-2.68%+4.14%-11.48%+16.42% 197B
-3.07%+11.36%-8.14%+17.40% 128B
-2.24%+6.24%+13.88%+39.69% 128B
+0.96%+5.15%-38.02%+12.24% 99B
-1.11%+1.49%-6.79%+70.55% 64.82B
+0.01%+8.05%+20.53%-17.48% 58.17B
+0.91%+23.02%-4.99%+60.30% 52.84B
-6.98%-14.94%-9.70%+46.32% 50.69B
-2.36%+3.72%+3.27%-8.07% 37.23B
Average -1.31%+5.41%+13.58%+49.17% 82.84B
Weighted average by Cap. -1.86%+7.30%-3.44%+28.80%

Financials

2026 *2027 *
Net sales 781M 700M 640M 584M 1.1B 73.37B 1.14B 7.71B 3.08B 39.15B 2.93B 2.87B 124B 1B 900M 823M 751M 1.41B 94.33B 1.46B 9.91B 3.95B 50.33B 3.77B 3.69B 159B
Net income -17.36M -15.57M -14.23M -12.99M -24.48M -1.63B -25.25M -172M -68.41M -871M -65.18M -63.78M -2.75B 76.26M 68.4M 62.51M 57.06M 108M 7.17B 111M 753M 300M 3.83B 286M 280M 12.08B
Net Debt -149M -134M -122M -112M -210M -14.03B -217M -1.47B -588M -7.49B -560M -548M -23.63B -298M -267M -244M -223M -420M -27.98B -433M -2.94B -1.17B -14.93B -1.12B -1.09B -47.14B
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
07/11/26 US$227.12 +3.25% 406,012
05/11/26 US$219.98 -10.83% 2,042,313
04/11/26 US$246.70 +5.86% 2,081,409
03/11/26 US$233.04 -2.33% 10,738,722
02/11/26 US$238.61 +0.43% 1,665,262
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
219.98USD
Average target price
242.46USD
Spread / Average Target
+10.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glaukos Corporation
  1. Stock Market
  2. Stocks
  3. GKOS Stock